Latest Insider Transactions at Oncology Institute, Inc. (TOI)
This section provides a real-time view of insider transactions for Oncology Institute, Inc. (TOI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncology Institute, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncology Institute, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2025
|
Richard A Barasch Director |
BUY
Conversion of derivative security
|
Indirect |
620,400
+19.53%
|
-
|
|
Jun 17
2025
|
Richard A Barasch Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
311,128
-9.62%
|
$622,256
$2.62 P/Share
|
|
Jun 17
2025
|
Richard A Barasch Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
679,224
+17.35%
|
$679,224
$1.2 P/Share
|
|
Jun 17
2025
|
Richard A Barasch Director |
BUY
Conversion of derivative security
|
Direct |
159,500
+7.61%
|
-
|
|
Jun 05
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Indirect |
76,324
-5.66%
|
$228,972
$3.05 P/Share
|
|
Jun 05
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Direct |
673,676
-4.61%
|
$2,021,028
$3.05 P/Share
|
|
Jun 03
2025
|
Brad Hively Director |
SELL
Open market or private sale
|
Direct |
1,976,137
-43.82%
|
$3,952,274
$2.87 P/Share
|
|
Jun 03
2025
|
Brad Hively Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,867,605
+18.43%
|
$1,867,605
$1.01 P/Share
|
|
May 21
2025
|
Jeffrey Langsam Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,380
+50.0%
|
-
|
|
May 21
2025
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,388
-1.13%
|
$40,776
$2.67 P/Share
|
|
May 21
2025
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,801
-0.76%
|
$3,602
$2.67 P/Share
|
|
May 21
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,601
-0.68%
|
$3,202
$2.67 P/Share
|
|
May 21
2025
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,636
-2.23%
|
$11,272
$2.67 P/Share
|
|
May 20
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Indirect |
203,532
-13.11%
|
$407,064
$2.71 P/Share
|
|
May 20
2025
|
M33 Growth I L.P. Director |
SELL
Open market or private sale
|
Direct |
1,796,468
-10.94%
|
$3,592,936
$2.71 P/Share
|
|
Mar 31
2025
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
157,088
+39.95%
|
-
|
|
Mar 31
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
197,368
+45.46%
|
-
|
|
Mar 31
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,281
+39.11%
|
-
|
|
Mar 31
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,083,334
+37.47%
|
-
|
|
Mar 26
2025
|
M33 Growth I L.P. Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,716,898
+14.2%
|
$2,716,898
$1.04 P/Share
|
|
Mar 26
2025
|
Daniel Virnich Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
22,640
+3.03%
|
$22,640
$1.04 P/Share
|
|
Mar 26
2025
|
Yale Podnos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+10.28%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Mark L Pacala Director |
BUY
Open market or private purchase
|
Indirect |
90,562
+28.7%
|
$90,562
$1.04 P/Share
|
|
Mar 26
2025
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
9,056
+1.32%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Karen Marie Johnson Director |
BUY
Open market or private purchase
|
Direct |
36,224
+15.12%
|
$36,224
$1.04 P/Share
|
|
Mar 26
2025
|
Jeremy Castle Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+9.11%
|
$9,056
$1.04 P/Share
|
|
Mar 26
2025
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Indirect |
1,358,448
+43.34%
|
$1,358,448
$1.04 P/Share
|
|
Mar 26
2025
|
Robert Ross Carter Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,056
+18.69%
|
$9,056
$1.04 P/Share
|
|
Mar 19
2025
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,261
-1.44%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,150
-3.65%
|
$0
$0.89 P/Share
|
|
Mar 19
2025
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,975
-4.08%
|
$0
$0.89 P/Share
|
|
Jan 06
2025
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
258
-0.81%
|
$0
$0.34 P/Share
|
|
Dec 03
2024
|
Jeremy Castle Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,130
-1.37%
|
$0
$0.16 P/Share
|
|
Dec 02
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
50,000
+6.98%
|
$0
$0.15 P/Share
|
|
Nov 26
2024
|
Brad Hively Director |
BUY
Open market or private purchase
|
Direct |
250,000
+28.84%
|
$0
$0.17 P/Share
|
|
Nov 22
2024
|
Richard A Barasch Director |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+16.09%
|
-
|
|
Nov 22
2024
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+27.11%
|
-
|
|
Nov 22
2024
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+23.72%
|
-
|
|
Nov 22
2024
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+23.4%
|
-
|
|
Nov 22
2024
|
Gabriel Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.84%
|
-
|
|
Nov 22
2024
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+24.01%
|
-
|
|
Nov 22
2024
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+5.76%
|
-
|
|
Nov 20
2024
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,002
-1.33%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Robert Ross Carter Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
235
-0.73%
|
$0
$0.14 P/Share
|
|
Nov 20
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,727
-0.68%
|
$0
$0.14 P/Share
|
|
Nov 12
2024
|
Brad Hively Director |
SELL
Other acquisition or disposition
|
Direct |
353,450
-49.08%
|
-
|
|
Nov 12
2024
|
Yale Podnos Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
28,398
-14.6%
|
-
|
|
Nov 12
2024
|
Daniel Virnich Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
195,236
-11.24%
|
-
|
|
Nov 12
2024
|
Mark L Pacala Director |
SELL
Other acquisition or disposition
|
Direct |
50,620
-20.73%
|
-
|
|
Aug 16
2024
|
Havencrest Healthcare Partners, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
16,333,241
-74.63%
|
-
|